This detrimental effect of reduced CD34-MVD on prognosis has been found not only in NSCLC [16] but also in other malignancies, such as kidney cancer [23], bladder cancer [24], ovarian cancer [25], intrahepatic cholangiocarcinoma [26], and hepatocellular carcinoma [27]. Here, CD34 is linked to ovarian cancer.